VIP会员
| 中文名: | 帕纳替尼;Ponatinib |
| 中文别名: | AP 24534; AP-24534;3-(2-咪唑并[1,2-b]哒嗪-3-乙炔基)-4-甲基-N-[4-[(4-甲基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]苯甲酰胺; |
| 英文名称： | AP24534(Ponatinib) |
| 英文别名： | AP 24534; AP24534; AP-24534;3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
| CAS No.: | 943319-70-8 |
| 分子式: | C29H27F3N6O |
| 分子量: | 532.56 |
| 性状: | 属性溶解性Soluble in DMSO (100 mM), ethanol (50 mM), methanol, and water (<1 mg/ml) at 25 °C.存贮条件储存温度-20°C熔点>160 °C描述产品介绍Ponatinib (AP24534)是一种新型有效的作用于Abl， PDGFRα， VEGFR2， FGFR1和Src的多靶点抑制剂， IC50分别为0.37 nM， 1.1 nM， 1.5 nM， 2.2 nM和5.4 nM。用途A Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor生化机理AP 24534 is a small molecule, multi-target kinase inhibitor known to potently inhibit Bcr-Abl (the fusion protein of Bcr and c-Abl), Flk-1(VEGFR2) and FGFR. It also exhibits inhibitory activity against PDGFRα, c-Src and c-Kit. AP 24534 inhibits the proliferation of mutant FLT3-positive cells (IC50 of 13 nM), which inhibits mutant FLT3 phosphorylation (IC50 of 1 nM) and the proliferation of Bcr-Abl1 T315I-positive Ba/F3 cells with an IC50 of 8 nM.包装P127550-10mg,P127550-50mg,P127550-250mg in glass bottle |
| 储存: | 储存温度-20°C |
| 安全术语: | |
| 风险术语: | |
| 危险品标志: | |
| 危险品运输编号: | |
| 用途: | AP24534 is a novel potent, orally available small molecule multitargeted kinase inhibitor with IC50 of 0.37, 2, 1.5, 2.2, 1.1, 1and 0.24 nM for native pan-BCR-ABL, mutated form, VEGFR2, FGFR1, PDGFRα, mutant FLT3 phosphorylation and LYN. |
粤公网安备44196802000105号
400-6226-992